CEMP News Alert Cempra Inc (CEMP) 18.17 12/17/2014 00:49:26

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cempra Inc (CEMP) 18.17 $CEMP

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 85.87 (-0.33), BMRN: 86.06 (-1.17), TGTX: 16.78 (-0.22), BMY: 57.69 (-0.86), MACK: 10.08 (+0.20), FMI: 20.73 (-0.15), RNA: 18.55 (+0.24), GWPH: 67.64 (-0.49), SRPT: 12.60 (-0.40), MRK: 56.80 (-0.15), NLNK: 33.10 (-0.36), ICPT: 129.30 (-4.61), THLD: 2.91 (unch), CEMP: 18.17 (-0.26), NVS: 91.65 (+0.01)

Cempra (CEMP) Is Today's Strong On High Volume Stock
at The Street - Fri Dec 12, 9:13AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
CEMP: 18.17 (-0.26)

Will Cempra (CEMP) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:20AM CST
Will Cempra (CEMP) Continue to Surge Higher?
CEMP: 18.17 (-0.26)

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/24xkp9/communityacquired) has announced the addition of the "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Bacterial Pneumonia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Actavis plc - Cempra, Inc. - Pfizer Inc. - Cempra Pharmaceuticals, Inc. - AstraZeneca PLC - Nabriva Therapeutics AG - Cubist Pharmaceuticals, Inc. - Boehringer Ingelheim Auslandsbeteiligungs GmbH - Bayer AG - Basilea Pharmaceutica AG Clinical Trial Overview of Top Institutes / Government - Yokohama Rosai Hospital - Nagasaki Evaluation Organization for Clinical Interventions - Central Japan Lung Study Group - Albany Medical Center For more information visit http://www.researchandmarkets.com/research/24...tyacquired
CBSTZ: 0.06 (unch), PFE: 30.67 (-0.19), AZN: 69.56 (-0.18), CEMP: 18.17 (-0.26)

Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OFED: 19.01 (-0.99), EFOI: 5.20 (-0.50), CBST: 96.73 (+0.42), AKAO: 11.97 (+0.05), CEMP: 18.17 (-0.26), PDCE: 34.04 (+2.10), MTEX: 29.26 (-0.14), OTIC: 40.00 (+3.23)

Analysts say two biotech firms may be targets after Merck-Cubist deal
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 12:20PM CST

AKAO: 11.97 (+0.05), CEMP: 18.17 (-0.26)

Cempra (CEMP) in Focus: Stock Rises 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 7:37AM CST
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise more than 11% on the day.
LCI: 42.70 (-1.35), CEMP: 18.17 (-0.26), IG: 8.78 (+0.18), BIOD: 1.30 (-0.02)

Can Cempra (CEMP) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:52AM CST
Cempra has been witnessing a nice streak of beating earnings estimates. In fact, the company currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming beat
CEMP: 18.17 (-0.26)

Cempra to Participate in Upcoming Investor Events in December
GlobeNewswire - Wed Dec 03, 3:10PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor events in December. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 18.17 (-0.26)

Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST

TTPH: 30.02 (+0.70), CBST: 96.73 (+0.42), ROG: 68.30 (+0.05), CEMP: 18.17 (-0.26)

Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies
GlobeNewswire - Wed Nov 19, 5:00AM CST
$16.0 Million Will be Provided to Cover the Cost of the Study and Other Activities Specified in the Contract
CEMP: 18.17 (-0.26)

Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Life Sciences Report - Seeking Alpha - Thu Nov 13, 3:24PM CST
What do you get when you combine a top-ranked industry analyst with a retired lieutenant colonel from the U.S. Marine Corps? You get Steve Brozak, who brings his one-of-a kind perspective on the intricacies of Ebola virus disease to this interview...
TTPH: 30.02 (+0.70), JNJ: 102.76 (-1.20), BCRX: 10.23 (+0.14), NAVB: 1.50 (-0.05), CMRX: 34.77 (-0.27), SRPT: 12.60 (-0.40), NBS: 3.23 (+0.01), TKMR: 13.12 (-0.19), GSK: 41.92 (+0.62), CEMP: 18.17 (-0.26), OMER: 20.51 (-0.62)

Sucampo (SCMP) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:25AM CST
Sucampo Pharmaceuticals (SCMP) was a big mover last session, with shares rising over 7% on the day.
LCI: 42.70 (-1.35), SHPG: 208.76 (+0.28), SCMP: 12.89 (+0.23), CEMP: 18.17 (-0.26)

Cempra to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 3:11PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 18.17 (-0.26)

Moving Average Crossover Alert: Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:10AM CST
Moving Average Crossover Alert: Cempra (CEMP)
CEMP: 18.17 (-0.26)

Why Cempra (CEMP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:31AM CST
Cempra has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well
CEMP: 18.17 (-0.26)

Strength Seen in Cempra (CEMP): Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:25AM CDT
Cempra (CEMP) was a big mover last session, with shares rising over 10% on the day.
LCI: 42.70 (-1.35), ADHD: 3.56 (+0.27), CEMP: 18.17 (-0.26), IG: 8.78 (+0.18)

More on Cempra Holdings Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:47AM CDT

CEMP: 18.17 (-0.26)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 224

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Merit Medical Systems: Price Target Raised Amid Strong Growth Prospects

Updated Category News Views 92

Merit Medical Systems Price Target Increased by Baird Baird has enhanced its price target for Merit Medical Systems, Inc. (NASDAQ: MMSI) from $96.00 to $107.00, keeping an Outperform rating on the stock. This adjustment anticipates that the company will surpass its organic growth rate and earnings per share (EPS) expectations for the upcoming quarter. Confidence in Future...

Continue Reading
Qualifacts Is Enhancing Collaborative Workspaces in Tampa

Updated Category News Views 122

Qualifacts Consolidates Tampa Operations into a Modern Office Qualifacts, a prominent player in the field of electronic health records (EHR) and data solutions tailored for behavioral health and human services organizations, has made a significant move by consolidating its two smaller offices in Tampa. The company has transitioned into a new, modern location designed to...

Continue Reading
Unlocking the Potential of Neuromarketing for Digital Strategies

Updated Category News Views 140

Understanding Neuromarketing and Its Impact In today's competitive landscape, businesses are continuously seeking ways to enhance their digital marketing strategies. One approach gaining momentum is neuromarketing, which delves into the psychology behind user behavior. A recent article from Digital Silk explores how neuromarketing principles can guide organizations in...

Continue Reading
Monkee's of Loudoun Opens to Cheers and Elegance

Updated Category News Views 187

Bringing Southern Charm to Loudoun We've all seen those places where people parade in with snooty airs and pricetags that could feed a family for a week, but this one feels different. Monkee’s of Loudoun isn’t just rolling in the racks of high fashion — it’s bringing the allure of the South with a sprinkle of luxury and empathy. This franchise is no amateur,...

Continue Reading
PG&E Critiques Senate Bill 492's Wildfire Solutions

Updated Category News Views 60

PG&E's Take on Senate Bill 492: More to Be Desired Sit down for a moment, because PG&E's not mincing words with their latest statement. Talking about Senate Bill 492, PG&E puts it plain and clear—this legislation is just skirting around the edges of what's really needed to tackle California's wildfire crisis. In their eyes, it's like putting a band-aid on a wound that...

Continue Reading